Comparison Between the Efficacy of Ultrasound-guided Erector Spinae Plane Block and Conventional Treatment for Pain Management in Patients With Post-herpetic Neuralgia

NCT ID: NCT07256145

Last Updated: 2025-12-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-08-01

Study Completion Date

2026-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The present study aims to evaluate the efficacy of ultrasound-guided erector spinae plane block with steroids to relieve pain in cases of post-herpetic neuralgia, patient satisfaction, and record any complications post-injection.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The current study will be conducted as a single-blinded prospective randomized controlled study to evaluate the efficacy of ultrasound-guided erector spinae plane block with steroids to relieve pain in cases of post-herpetic neuralgia.

All patients will be evaluated by:

* Full history taking: including age, sex, presence of co-morbid conditions as well as the presenting complaint.
* Clinical examination and routine lab investigations that include:

* Complete blood count (CBC).
* Fasting blood glucose (FBG).
* Coagulation profile (bleeding time, prothrombin time, prothrombin activity, international normalized ratio).

Measurements:

Patients will be followed up at 24 hours, 1 week, and 6 weeks after injection.

The following measurements will be recorded:

1. Pain will be assessed pre- and post-injection using VAS score at 24 hours, 1 week, and 6 weeks post-injection.
2. Need for analgesic intake post-injection will be assessed at the follow-up periods.
3. Patient satisfaction using the SAPS score.
4. Complications post-injection as pain, irritation or infection will be assessed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Post-Herpetic Neuralgia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Injection group

Group Type EXPERIMENTAL

erector spinae plane block

Intervention Type PROCEDURE

erector spinae plane block with steroids

conventional group

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

erector spinae plane block

erector spinae plane block with steroids

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with post-herpetic neuralgia not responding to medical treatment.

Exclusion Criteria

\- 1- Patient refusal 2- Age less than 20 years or older than 70 years. 3- Systemic Infection. 4-Patients with dementia or other diseases that could have impaired their memory or cognitive function.

5- Immunocompromised patients, severe osteoporosis, and uncontrolled diabetes mellitus.
Minimum Eligible Age

20 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Alexandria University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Alexandria University

Alexandria, Aleexandria, Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

yasmine ragab elsayed, MD

Role: primary

00201001972418

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0307429

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.